Abstract
Cell cycle checkpoints are surveillance mechanisms that monitor and coordinate the order and fidelity of cell cycle events. When defects in the division program of a cell are detected, checkpoints prevent the pursuant cell cycle transition through regulation of the relevant cyclin-cdk complex(es). Checkpoints that respond to DNA damage have been described for the G1, S and G2 phases of the cell cycle. The p53 tumour suppressor is a key regulator of G1/S checkpoints, and can promote cell cycle delay or apoptosis in response to DNA damage. The importance of these events to cellular physiology is highlighted by the fact that tumours, in which p53 is frequently mutated, have widespread defects in the G1/S DNA damage checkpoints and a heightened level of genomic instability. G2/M DNA damage checkpoints have been defined by yeast genetics, though the genes in this response are conserved in mammals. We show here using biochemical and physiological assays that p53 is dispensable for a DNA damage checkpoint activated in the G2 phase of the cell cycle. Moreover, upregulation of p53 through serine 20 phosphorylation, does not occur in G2. Conversely, we show that the Chk1 protein kinase is essential for the human G2 DNA damage checkpoint. Importantly, inhibition of Chk1 in p53 deficient cells greatly sensitizes them to radiation, validating the hypothesis of targeting Chk1 in rational drug design and development for anti-cancer therapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Blasina A, Paegle ES, McGowan CH . 1997 Mol. Cell. Biol. 8: 1013–1023
Booher RN, Holman PS, Fattaey A . 1997 J. Biol. Chem. 272: 22300–22306
Brown EJ, Baltimore D . 2000 Genes Dev. 14: 397–402
Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B . 1999 Science 282: 1497–1501
Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD . 1998 Science 281: 1677–1679
Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B . 1999 Nature 401: 616–620
Chehab NH, Malikzay A, Appel M, Halazonetis TD . 2000 Genes Dev. 14: 278–288
Chen MS, Hurov J, White LS, Woodford-Thomas T, Piwnica-Worms H . 2001 Mol. Cell. Biol. 21: 3853–3861
Cliby WA, Roberts CJ, Cimprich KA, Stringer CM, Lamb JR, Schreiber SL, Friend SH . 1998 EMBO J. 17: 159–169
Curman D, Cinel B, Williams DE, Rundle N, Block WD, Goodarzi AA, Hutchins JR, Clarke PR, Zhou BB, Lees-Miller SP, Andersen RJ, Roberge M . 2001 J. Biol. Chem. 276: 17914–17919
Dunphy WG . 1994 Trends Cell Biol. 4: 202–207
El-Deiry W, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B . 1993 Cell 75: 817–825
Elledge SJ . 1996 Science 274: 1664–1672
Fattaey A, Booher RN . 1997 Prog. Cell Cycle Res. 3: 233–240
Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, Piwnica-Worms H . 2000 J. Biol. Chem. 275: 5600–5605
Guo Z, Kumagai A, Wang SX, Dunphy WG . 2000 Genes Dev. 14: 2745–2756
Heald R, McLoughlin M, McKeon F . 1993 Cell 74: 463–474
Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ, Mak TW . 2000 Science 287: 1824–1827
Hobbs S, Jitrapakdee S, Wallace JC . 1998 Biochem. Biophys. Res. Comm. 252: 368–372
Hunter T, Pines J . 1994 Cell 79: 573–582
Jackson JR, Gilmartin A, Imbrugia C, Winkler JD, Marshall LA, Roshak A . 2000 Cancer Res. 60: 566–572
Jin P, Gu Y, Morgan DO . 1996 J. Cell Biol. 134: 963–970
Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW . 1991 Cancer Res. 51: 6304–6311
Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, Hobson K, Taya Y, Gabrielli B, Chan D, Lees-Miller SP, Lavin MF . 1998 Nat. Genet. 20: 398–400
Kraker AJ, Choy DF, Boushelle SL, Moore CW, Garrett MD, Booher RN . 2000 Proc. Am. Assoc. Cancer Res. 41: 468
Kumagai A, Guo Z, Emani KH, Wang SX, Dunphy WG . 1998 J. Cell Biol. 142: 1559–1569
Kunkel TA, Roberts JD, Zakour RA . 1987 Methods Enzymol 154: 367–382
Lengauer C, Kinzler KW, Vogelstein B . 1998 Nature 396: 643–649
Leu JY, Roeder GS . 1999 Mol. Cell 4: 805–814
Levine AJ . 1997 Cell 88: 323–331
Liu F, Stanton JJ, Wu Z, Piwnica-Worms H . 1997 Mol. Cell. Biol. 17: 571–583
Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, Donehower LA, Elledge SJ . 2000 Genes Dev. 14: 1448–1459
Lopez-Girona A, Kanoh J, Russell P . 2001 Curr. Biol. 11: 50–54
Masui Y, Wang P . 1998 Biol. Cell 90: 537–548
Michael WM, Newport J . 1998 Science 282: 1886–1889
Muschel RJ, Zhang HB, McKenna WG . 1993 Cancer Res. 53: 1128–1135
Nurse P . 1990 Nature 344: 503–508
O'Connell MJ, Norbury C, Nurse P . 1994 EMBO J. 13: 4926–4937
O'Connell MJ, Raleigh JM, Verkade HD, Nurse P . 1997 EMBO J. 16: 545–554
O'Connell MJ, Walworth NC, Carr AM . 2000 Trends Cell Biol. 10: 296–303
Ogg S, Gabrielli B, Piwnica-Worms H . 1994 J. Biol. Chem. 269: 30461–30469
Oren M . 1999 J. Biol. Chem. 274: 36031–36034
Parker LL, Atherton-Fessler S, Lee MS, Ogg S, Falk JL, Swenson KI, Piwnica-Worms H . 1991 EMBO J. 10: 1255–1263
Poon RYC, Jiang W, Toyoshima H, Hunter T . 1996 J. Biol. Chem. 271: 13283–13291
Raleigh JM, O'Connell MJ . 2000 J. Cell Sci. 113: 1727–1736
Rhind N, Furnari B, Russell P . 1997 Genes Dev. 11: 504–511
Roberge M, Berlinck RG, Xu L, Anderson HJ, Lim LY, Curman D, Stringer CM, Friend SH, Davies P, Vincent I, Haggarty SJ, Kelly MT, Britton R, Piers E, Andersen RJ . 1998 Cancer Res. 58: 5701–5706
Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, Elledge SJ . 1997 Science 277: 1497–1501
Schmidt-Kastner PK, Jardine K, Cormier M, McBurney MW . 1998 Oncogene 16: 3003–3011
Sherr CJ, Roberts JM . 1999 Genes Dev. 13: 1501–1512
Shieh SY, Ahn J, Tamai K, Taya Y, Prives C . 2000 Genes Dev. 14: 289–300
Taylor WR, Stark GR . 2001 Oncogene 20: 1803–1815
Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C, Abraham RT . 1999 Genes Dev. 13: 152–157
White E . 1996 Genes Dev. 10: 1–15
Zhao H, Piwnica-Worms H . 2001 Mol. Cell Biol. 21: 4129–4139
Acknowledgements
We thank Drs B Vogelstein and P Rao for the prevision of reagents, Alan J Kraker for communication of results prior to their publication, and Doris Germain for critical reading of the manuscript. This work was supported by grants from the NHMRC. A Cuddihy is a Fellow, and M O'Connell a Scholar, of the Leukemia and Lymphoma Society.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Koniaras, K., Cuddihy, A., Christopoulos, H. et al. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 20, 7453–7463 (2001). https://doi.org/10.1038/sj.onc.1204942
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204942
Keywords
This article is cited by
-
Biomedical association analysis between G2/M checkpoint genes and susceptibility to HIV-1 infection and AIDS progression from a northern chinese MSM population
AIDS Research and Therapy (2023)
-
Syntaxin 18 regulates the DNA damage response and epithelial-to-mesenchymal transition to promote radiation resistance of lung cancer
Cell Death & Disease (2022)
-
Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling
Journal of Experimental & Clinical Cancer Research (2020)
-
Molecularly targeted therapies for p53-mutant cancers
Cellular and Molecular Life Sciences (2017)
-
Exploiting replicative stress to treat cancer
Nature Reviews Drug Discovery (2015)